

**From:** [HRSA Paperwork](#)  
**To:** [Volpe, Josh \(HRSA\)](#); [Stubbins, Amanda \(HRSA\)](#); [Zadecky, Julie \(HRSA\)](#)  
**Cc:** [Miller, Samantha \(HRSA\)](#); [Dooley, Leslie \(HRSA\)](#); [Bourassa, Catherine \(HRSA\)](#); [HRSA Paperwork](#)  
**Subject:** FW: NASTAD Comments re: Enrollment and Re-Certification of Entities in the 340B Drug Pricing Program, OMB No. 0915-0327  
**Date:** Thursday, September 25, 2025 8:00:00 AM  
**Attachments:** [NASTAD Comments 340B Registration Recertification ICR OMB 0915-0327.pdf](#)

---

Good morning, everyone

We received the attached comment on the 340B Drug Pricing Forms, 60-day (OMB # 0915-0327). Please review and address the comment. Please review and address the comment. This can be done through 1) Your Bureau/Office providing the response directly to the commenter; 2) preparing a formal response for the PRA Team to send via [paperwork@hrsa.gov](mailto:paperwork@hrsa.gov); 3) Providing a response to the comment in the Supporting Statement A.

Regardless of the option that is taken, the 30-day FRN and the Supporting Statement must list the number of comments received as well as a brief description of the main points of the comments and the Bureau/Office response. If changes are requested to the collection that are not adopted, please provide some language in the 30-day FRN and the Supporting Statement explaining why.

HRSA Paperwork Team

---

**From:** Stephen Lee <slee@nastad.org>  
**Sent:** Wednesday, September 24, 2025 10:00 AM  
**To:** HRSA Paperwork <paperwork@hrsa.gov>  
**Subject:** [EXTERNAL] NASTAD Comments re: Enrollment and Re-Certification of Entities in the 340B Drug Pricing Program, OMB No. 0915-0327

Good Morning,

NASTAD appreciates the opportunity to submit the attached comments in response to the proposed Information Collection Request (ICR) regarding the registration and recertification of entities in the 340B Drug Pricing Program.

NASTAD represents the public health officials who administer HIV and viral hepatitis programs in all 50 U.S. states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and the U.S. Pacific Island Jurisdictions, including U.S. Centers for Disease Control and Prevention Division of HIV Prevention and Division of Viral Hepatitis grantees authorized under Section 318 of the Public Health Service Act likely to be impacted by the proposed 340B registration and

recertification requirements.

Thank you,

Stephen Lee MD, MBA, DHSM

Executive Director

Pronouns: He/Him/His

202.897.0028 | [slee@NASTAD.org](mailto:slee@NASTAD.org)

Connect with us: [LinkedIn](#) | [Facebook](#) | [Twitter](#) | [YouTube](#)

**NASTAD** | [444 North Capitol Street NW, Suite 339 | Washington, DC 20001](#) | [NASTAD.org](http://NASTAD.org)

This email and any files transmitted with it are confidential and intended solely for the use of the entity to whom they are addressed. If you received this email in error, please notify the sender.

**CAUTION:** This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and are confident the content is safe.